%0 Journal Article %A Camila Rosat Consiglio %A Nicola Cotugno %A Fabian Sardh %A Christian Pou %A Donato Amodio %A Lucie Rodriguez %A Ziyang Tan %A Sonia Zicari %A Alessandra Ruggiero %A Giuseppe Rubens Pascucci %A Veronica Santilli %A Tessa Campbell %A Yenan Bryceson %A Daniel Eriksson %A Jun Wang %A Alessandra Marchesi %A Tadepally Lakshmikanth %A Andrea Campana %A Alberto Villani %A Paolo Rossi %A the CACTUS study team %A Nils Landegren %A Paolo Palma %A Petter Brodin %T The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19 %D 2020 %R 10.1101/2020.07.08.20148353 %J medRxiv %P 2020.07.08.20148353 %X SARS-CoV-2 infection is typically very mild and often asymptomatic in children. A complication is the rare Multisystem Inflammatory Syndrome in Children (MIS-C) associated with COVID-19, presenting 4-6 weeks after infection as high fever, organ dysfunction and strongly elevated markers of inflammation. The pathogenesis is unclear but has overlapping features with Kawasaki disease suggestive of vasculitis and a likely autoimmune etiology. We apply systems-level analyses of blood immune cells, cytokines and autoantibodies in healthy children, children with Kawasaki disease enrolled prior to COVID-19, children infected with SARS-CoV-2 and children presenting with MIS-C. We find that the inflammatory response in MIS-C differs from the cytokine storm of severe acute COVID-19, shares several features with Kawasaki disease, but also differs from this condition with respect to T-cell subsets, IL-17A and biomarkers associated with arterial damage. Finally, autoantibody profiling suggests multiple autoantibodies that could be involved in the pathogenesis of MIS-C.HIGHLIGHTS Hyperinflammation in MIS-C differs from that of acute COVID-19T-cell subsets discriminate Kawasaki disease patients from MIS-CIL-17A drives Kawasaki, but not MIS-C hyperinflammation.Global autoantibodies profiling indicate possibly pathogenic autoantibodiesCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was made possible by a grant from Knut and Alice Wallenberg Foundation (KAW) to SciLifeLab as well as donations from Bure Equity AB and Jonas and Christina af Jochnick Foundation to Karolinska Institutet and P.B. The authors are also grateful for support from Childrens Hospital Bambino Gesu ricerca corrente 2020 to NC and ricerca corrente 2019 to PP.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The OPBG Ethics Committees approved studies of Italian patients while the Swedish Ethical review authority approved the study protocol for Swedish patients (ID:2020-01911). Autoantibody analyses in APS-1 patients were approved by Ethical board of Stockholm (ID: 2016/2553-31/2). Informed consent was obtained from parents or guardians of all patients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data is freely available for download: https://brodinlab.com/data-repository/ Scripts to reproduce the analyses are available through GitHub: https://github.com/Brodinlab/MIS-C_manuscript https://brodinlab.com/data-repository/ %U https://www.medrxiv.org/content/medrxiv/early/2020/08/11/2020.07.08.20148353.full.pdf